Clinical trials: GEP-NET, open to volunteers
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- NCT07165132
- Testing
- RYZ401
- Where
- 14 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- RayzeBio, Inc.
Neuroendocrine Tumors, Intestinal Neoplasms
Spanish Series of Patients Treated With the Radionuclide Lutetium177
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of…
- Conditions
- Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
- Trial name
- SEPTRALU (NCT04949282)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 20 sites in Spain
- Volunteers
- 5,000 people
- Sponsor
- Sociedad Española de Medicina Nuclear e Imagen Molecular
Gastroenteropancreatic Neuroendocrine Tumor, Radiotherapy
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
Operandi project aims to address unmet clinical needs in the current management of GEP-NETs treated with PRRT by exploring new opportunities provided by imaging-based (AI algorithms) and data augmentation, simultaneous…
- Trial name
- OPERANDI-NET (NCT06256705)
- Testing
- Simultaneous 68Ga-DOTATOC PET-MRI
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas.
- Conditions
- Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- PReCedeNT (NCT07185672)
- Testing
- Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE, Capecitabine plus temozolamide
- Where
- 2 sites in India
- Volunteers
- 162 people
- Sponsor
- Tata Memorial Hospital
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1…
- Conditions
- Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06016855
- Testing
- Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center